These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2344717)

  • 21. Risk-adapted induction and consolidation therapy in adults with de novo AML aged Heil G; Krauter J; Raghavachar A; Bergmann L; Hoelzer D; Fiedler W; Lübbert M; Noens L; Schlimok G; Arnold R; Kirchner H; Ganser A
    Ann Hematol; 2004 Jun; 83(6):336-44. PubMed ID: 15034758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia.
    De Witte T; Muus P; De Pauw B; Haanen C
    Cancer; 1990 Sep; 66(5):831-7. PubMed ID: 2386911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical characteristics of patients with de novo acute myeloid leukaemia and isolated trisomy 11: a Cancer and Leukemia Group B study.
    Heinonen K; Mrózek K; Lawrence D; Arthur DC; Pettenati MJ; Stamberg J; Qumsiyeh MB; Verma RS; MacCallum J; Schiffer CA; Bloomfield CD
    Br J Haematol; 1998 Jun; 101(3):513-20. PubMed ID: 9633896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy.
    Hu XM; Liu F; Zheng CM; Li L; Liu C; Zhang SS; Xiao HY; Yang XH; Wang HZ; Xu YG; Hu NP; Ma R
    Chin J Integr Med; 2009 Jun; 15(3):193-7. PubMed ID: 19568712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival in 91 adults with acute myelogenous leukaemia treated with 1-6 intensive courses of chemotherapy.
    Evensen SA; Brinch L; Stavem P; Tjønnfjord G
    J Intern Med; 1992 Nov; 232(5):433-7. PubMed ID: 1453128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of myeloperoxidase containing blast cells in acute myelogenous leukaemia.
    Advani SH; Hegde UP; Iyer RS; Gopal R; Saikia TK; Pai SK; Nair CN; Kurkure PA; Pai VR; Nadkarni KS
    Indian J Med Res; 1993 Feb; 98():8-14. PubMed ID: 8388366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia.
    Fenaux P; Tertian G; Castaigne S; Tilly H; Leverger G; Guy H; Bordessoule D; Leblay R; Le Gall E; Colombat P
    J Clin Oncol; 1991 Sep; 9(9):1556-61. PubMed ID: 1805818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival.
    Goasguen JE; Matsuo T; Cox C; Bennett JM
    Leukemia; 1992 Jun; 6(6):520-5. PubMed ID: 1318461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
    J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.
    Parker JE; Pagliuca A; Mijovic A; Cullis JO; Czepulkowski B; Rassam SM; Samaratunga IR; Grace R; Gover PA; Mufti GJ
    Br J Haematol; 1997 Dec; 99(4):939-44. PubMed ID: 9432047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission.
    Stein AS; O'Donnell MR; Slovak ML; Nademanee A; Dagis A; Schmidt GM; Parker PM; Snyder DS; Smith EP; Somlo G; Margolin KA; Arber D; Niland J; Forman SJ
    Leukemia; 2000 Jul; 14(7):1191-6. PubMed ID: 10914541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The rate of disease progression predicts the quality of remissions following intensive chemotherapy for myelodysplastic syndromes.
    Hirst WJ; Mufti GJ
    Leuk Res; 1994 Nov; 18(11):797-804. PubMed ID: 7967705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Poor response to intensive chemotherapy in de novo acute myeloid leukaemia with trilineage myelodysplasia. Japan Adult Leukaemia Study Group (JALSG).
    Kuriyama K; Tomonaga M; Matsuo T; Kobayashi T; Miwa H; Shirakawa S; Tanimoto M; Adachi K; Emi N; Hiraoka A
    Br J Haematol; 1994 Apr; 86(4):767-73. PubMed ID: 7918070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diagnosis and treatment strategy for de novo AML with trilineage myelodysplasia].
    Kuriyama K
    Rinsho Ketsueki; 1994 Mar; 35(3):267-71. PubMed ID: 8158847
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reasons for treating secondary AML as de novo AML.
    Ostgård LS; Kjeldsen E; Holm MS; Brown Pde N; Pedersen BB; Bendix K; Johansen P; Kristensen JS; Nørgaard JM
    Eur J Haematol; 2010 Sep; 85(3):217-26. PubMed ID: 20456491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
    Parovichnikova EN; Loukianova IA; Troitskaya VV; Drokov MY; Lobaova TI; Kuzmina LA; Sokolov AN; Kokhno AV; Fidarova ZT; Baskhaeva GA; Gavrilina OA; Vasilyeva VA; Obukhova TN; Kuznetsova SA; Sudarikov AB; Dvirnik VN; Galtseva IV; Davidiva JO; Kulikov SM; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):14-22. PubMed ID: 30701918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy.
    Fenaux P; Morel P; Rose C; Lai JL; Jouet JP; Bauters F
    Br J Haematol; 1991 Apr; 77(4):497-501. PubMed ID: 2025575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia.
    Chen CC; Yang CF; Yang MH; Lee KD; Kwang WK; You JY; Yu YB; Ho CH; Tzeng CH; Chau WK; Hsu HC; Gau JP
    Ann Oncol; 2005 Aug; 16(8):1366-73. PubMed ID: 15956039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.